MASCC/ISOO Clinical Practice Statement: management of oral complications of immunotherapy.

ABSTRACT:

Purpose

The MASCC/ISOO Clinical Practice Statement (CPS) endeavors to develop a succinct instrument for clinicians, encapsulating essential practical information requisite for the management of oral complications in oncology patients. This CPS specifically addresses the management of oral complications associated with immunotherapy.

Methods

This CPS was formulated through a rigorous literature review, followed by a structured discussion among a consortium of leading experts, members of the Oral Care Study Group of MASCC/ISOO. Immunotherapeutic agents were identified utilizing PubMed, and then they were matched with the National Cancer Institute's compendium of Food and Drug Administration-approved immunotherapy drugs. The statement integrated information from the literature

SUBMITTER: Fregnani ER 

PROVIDER: S-EPMC12433365 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature